MASSDEVICE ON CALL — Technology titan Google (NSDQ:GOOG) is taking new interest in human health in the latest "moonshot" project coming out of its ambitious "X" lab, famous for self-driving cars and Google Glass.
Genomics/Molecular Diagnostics
Siemens sells clinical microbiology biz to Beckman Coulter
Empowering consumers through accurate genomic tests
By: Jeffrey Shuren, M.D., J.D.
We’ve come to recognize that almost every disease has a genetic component, and many consumers now are eager to know more about their genetic profiles. They need only send a sample of their DNA collected from their saliva or from a cheek swab to a company, and in exchange they’ll get back information about their genetic risk for development of future disease.
CardioDx resurrects IPO dreams
More than 5 months after ditching efforts to open on public markets, California-based CardioDx is ready to take another swing at an initial public offering.
In regulatory documents filed this week the molecular diagnostics maker assigned new underwriters, named a couple of new executives and added 2 members to its board of directors. CardioDx has not yet revealed exact timing or terms for the revived IPO.
Lumicell adds another $600,000 in funding
Imaging systems maker Lumicell Diagnostics amended a previously closed $1 million funding round after landing another $560,000 in financing from 2 new investors, regulatory filings show.
Illumina unveils highly sought $1,000 genome system | MassDevice.com On Call
MASSDEVICE ON CALL — California-based lifesciences firm Illumina’s (NSDQ:ILMN) this week unveiled that it had achieved the highly sought $1,000 mark for human DNA sequencing.
GE Healthcare offers $1.06B for trio of Thermo Fisher lifesciences units
Gene sequencing devices are ‘next generation’
By: Jeffrey Shuren, M.D.
Just for a moment, imagine a scenario in which you have an illness that has eluded diagnosis. The usual suspects have been ruled out and no one knows exactly what’s making you sick.
CardioDx spikes IPO
California molecular diagnostics company CardioDx spiked its initial public offering, citing "unfavorable market conditions," according to news reports.
The 5.8-million-share offering by Palo Alto-based CardioDx was slated to raise $92 million at a share price of $14-$16 apiece. The IPO, originally scheduled for yesterday, would have seen CardioDx shares trade under the "CDX" symbol.
CardioDx aims for $92M IPO
California molecular diagnostics company CardioDx unveiled new details of its initial public offering, slated to raise $92 million through shares priced at $14-$16 apiece.
Once the IPO launches, CardioDx will trade on the Nasdaq stock market under the symbol "CDX."
CardioDx IPO may fetch $86.3 million
CardioDx is planning something big, although it hasn’t released the full details of its upcoming initial public offering. The Palo Alto, Calif.-based genetic testing company filed preliminary documents for a maximum aggregate offering of up to $86.3 million.
CardioDx hasn’t yet released details of the offering, so the number of shares and individual pricing remains a mystery, but the company has laid out its plans for how it’ll spend the money it hopes to raise.